Worth reading
45Recurring
0–100. This measures how worthwhile something is to read, not how good or bad the company is.Direction
Mixed performance
Direction inferred from the company’s description.Scale
-24.4
% (year-on-year change in operating profit)Wording
Conditional
How definitive the wording is.Results for this period
First quarter2023年6月1日〜2023年8月31日ConsolidatedJapanese GAAPNet Sales14,021¥ millionYear on year +4.1%Progress 25.9%
Operating profit196¥ millionYear on year -24.4%Progress 30.6%
Ordinary income213¥ millionYear on year -22.3%Progress 31.2%
Net income attributable to owners of the parent162¥ millionYear on year -1.8%Progress 34.9%
The width of the band at each stage is based on revenue. The narrower it becomes toward the bottom, the smaller the proportion of revenue that remains as profit. The dotted outline is the full-year forecast and the band inside it is the result for this period. The progress rate is the result divided by the forecast.
Net income per share63.53円
Financial position at period-end
Total assets22,586¥ million
of which net assets 7,976 ¥ millionEquity ratio 35.2%vs. prior year-end +3.0pt
塗りつぶした部分が自己資本比率です。総資産のうち、返済のいらない自前の資金がどれだけかを表します。The thin vertical line indicates the level at the end of the previous fiscal year.
Segment revenueMedical device sales ¥13,997 million (YoY +4.1%), Medical Equipment Manufacturing and Sales ¥73 million (YoY +3.0%), Medical Mall Business ¥17 million (YoY +5.6%)
Segment profitMedical device sales ¥455 million (YoY -6.5%), Medical Equipment Manufacturing and Sales ¥7 million (YoY +47.8%), Medical Mall Business ¥1 million (YoY +663.1%)
Outlook and shareholder returns
Full-year earnings forecast
Net Sales¥54,215 million (YoY -6.8%)
Operating profit¥641 million (YoY -44.5%)
Ordinary income¥682 million (YoY -43.4%)
Net income¥464 million (YoY +111.8%)
Annual Dividend Forecast¥48 → ¥55
Factors Behind Changes in Business Performance
検査用機器等の設備投資需要が前年同期より増加したこと、検査・手術件数の回復による診療材料の売上回復・増加により医療機器消耗品が増加したこと等により売上高が増加した。一方、販売費及び一般管理費の増加により営業利益が減少した。
Disclosure regarding the going concern assumption
Not applicable.
Change in accounting policy
基準改正に伴う変更 Noそれ以外の変更 No見積りの変更 No修正再表示 No
Changes in the scope of consolidationNew Number of companies 1 / Company name 株式会社クロスウェブ / Excluded Number of companies 0 / Company name Not disclosed / Notes 表紙の重要な子会社の異動は無。本文では2023年7月25日付で同社を連結子会社としたと記載。
Breakdown of extraordinary income (loss)Extraordinary income Reversal of allowance for doubtful accounts ¥54 million / Extraordinary loss Not disclosed
Availability of Supplementary Financial Results MaterialsNo
Availability of Financial Results BriefingNo
Issued Shares at Period-End2,553,000 Shares
Treasury Shares at Period-End114 Shares
| Item | Details |
|---|---|
| Fiscal Period Classification | First quarter |
| Accounting standards | Japanese GAAP |
| Consolidated / non-consolidated | Consolidated |
| Period Covered | 2023年6月1日〜2023年8月31日 |
| Net Sales | ¥14,021 million (YoY +4.1%) |
| Operating profit | ¥196 million (YoY -24.4%) |
| Ordinary income | ¥213 million (YoY -22.3%) |
| Profit attributable to owners of the parent | ¥162 million (YoY -1.8%) |
| Net income per share | 63.53円 |
| Equity ratio | End of the current fiscal period 35.2% / End of previous period 32.2% |
| Total assets | ¥22,586 million |
| Net assets | ¥7,976 million |
| Full-year earnings forecast | Net Sales ¥54,215 million (YoY -6.8%) / Operating profit ¥641 million (YoY -44.5%) / Ordinary income ¥682 million (YoY -43.4%) / Net income ¥464 million (YoY +111.8%) |
| Annual Dividend Forecast | ¥48 → ¥55 |
| Segment revenue | Medical device sales ¥13,997 million (YoY +4.1%), Medical Equipment Manufacturing and Sales ¥73 million (YoY +3.0%), Medical Mall Business ¥17 million (YoY +5.6%) |
| Segment profit | Medical device sales ¥455 million (YoY -6.5%), Medical Equipment Manufacturing and Sales ¥7 million (YoY +47.8%), Medical Mall Business ¥1 million (YoY +663.1%) |
| Breakdown of extraordinary income (loss) | Extraordinary income Reversal of allowance for doubtful accounts ¥54 million / Extraordinary loss Not disclosed |
| Disclosure regarding the going concern assumption | Not applicable. |
| Change in accounting policy | Changes due to revisions to standards No / Other changes No / Change in accounting estimate No / Restatement No |
| Changes in the scope of consolidation | New Number of companies 1 / Company name 株式会社クロスウェブ / Excluded Number of companies 0 / Company name Not disclosed / Notes 表紙の重要な子会社の異動は無。本文では2023年7月25日付で同社を連結子会社としたと記載。 |
| Availability of Supplementary Financial Results Materials | No |
| Availability of Financial Results Briefing | No |
| Issued Shares at Period-End | 2,553,000 Shares |
| Treasury Shares at Period-End | 114 Shares |
| Factors Behind Changes in Business Performance | 検査用機器等の設備投資需要が前年同期より増加したこと、検査・手術件数の回復による診療材料の売上回復・増加により医療機器消耗品が増加したこと等により売上高が増加した。一方、販売費及び一般管理費の増加により営業利益が減少した。 |
Items this document does not state (13)
Operating MarginCash flows from operating activitiesCash flows from investing activitiesCash flows from financing activitiesCash and cash equivalents at end of periodRevision to Earnings ForecastPayout ratioShareholder Return PolicyRegional salesOrders received and order backlogDepreciation and amortizationImpairment lossMaterial subsequent events
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.検査用機器などの設備投資需要が前年同期より増加し、検査・手術件数の回復により診療材料や医療機器消耗品の売上が回復・増加した。一方、販売費及び一般管理費が増加したため営業利益が減少した。
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.